Neurodevelopmental and neurodegenerative models of schizophrenia: white matter at the center stage
- PMID: 24870447
- PMCID: PMC4059450
- DOI: 10.1093/schbul/sbu070
Neurodevelopmental and neurodegenerative models of schizophrenia: white matter at the center stage
Abstract
Schizophrenia is a disorder of cerebral disconnectivity whose lifetime course is modeled as both neurodevelopmental and neurodegenerative. The neurodevelopmental models attribute schizophrenia to alterations in the prenatal-to-early adolescent development. The neurodegenerative models identify progressive neurodegeneration as its core attribute. Historically, the physiology, pharmacology, and treatment targets in schizophrenia were conceptualized in terms of neurons, neurotransmitter levels, and synaptic receptors. Much of the evidence for both models was derived from studies of cortical and subcortical gray matter. We argue that the dynamics of the lifetime trajectory of white matter, and the consistency of connectivity deficits in schizophrenia, support white matter integrity as a promising phenotype to evaluate the competing evidence for and against neurodevelopmental and neurodegenerative heuristics. We develop this perspective by reviewing normal lifetime trajectories of white and gray matter changes. We highlighted the overlap between the age of peak of white matter development and the age of onset of schizophrenia and reviewed findings of white matter abnormalities prior to, at the onset, and at chronic stages of schizophrenia. We emphasized the findings of reduced white matter integrity at the onset and findings of accelerated decline in chronic stages, but the developmental trajectory that precedes the onset is largely unknown. We propose 4 probable lifetime white matter trajectory models that can be used as the basis for separation between the neurodevelopmental and neurodegenerative etiologies. We argue that a combination of the cross-sectional and longitudinal studies of white matter integrity in patients may be used to bridge the neurodevelopment and degeneration heuristics to advance schizophrenia research.
Keywords: diffusion tensor imaging; etiology of schizophrenia; white matter integrity.
© The Author 2014. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Figures
Similar articles
-
Translating ENIGMA schizophrenia findings using the regional vulnerability index: Association with cognition, symptoms, and disease trajectory.Hum Brain Mapp. 2022 Jan;43(1):566-575. doi: 10.1002/hbm.25045. Epub 2020 May 28. Hum Brain Mapp. 2022. PMID: 32463560 Free PMC article.
-
Two Patterns of White Matter Abnormalities in Medication-Naive Patients With First-Episode Schizophrenia Revealed by Diffusion Tensor Imaging and Cluster Analysis.JAMA Psychiatry. 2015 Jul;72(7):678-86. doi: 10.1001/jamapsychiatry.2015.0505. JAMA Psychiatry. 2015. PMID: 25993492
-
White matter development in infants at risk for schizophrenia.Schizophr Res. 2019 Aug;210:107-114. doi: 10.1016/j.schres.2019.05.039. Epub 2019 Jun 8. Schizophr Res. 2019. PMID: 31182322 Free PMC article.
-
White matter development in the early stages of psychosis.Schizophr Res. 2015 Jan;161(1):61-9. doi: 10.1016/j.schres.2014.05.021. Epub 2014 Jun 2. Schizophr Res. 2015. PMID: 24893908 Free PMC article. Review.
-
White matter alterations in early stages of schizophrenia: a systematic review of diffusion tensor imaging studies.J Neuroimaging. 2014 Mar-Apr;24(2):101-10. doi: 10.1111/j.1552-6569.2012.00779.x. Epub 2013 Jan 14. J Neuroimaging. 2014. PMID: 23317110 Review.
Cited by
-
Schizophrenia: from neurochemistry to circuits, symptoms and treatments.Nat Rev Neurol. 2024 Jan;20(1):22-35. doi: 10.1038/s41582-023-00904-0. Epub 2023 Dec 18. Nat Rev Neurol. 2024. PMID: 38110704 Review.
-
Potential diagnostic biomarkers for schizophrenia.Med Rev (2021). 2022 Aug 2;2(4):385-416. doi: 10.1515/mr-2022-0009. eCollection 2022 Aug. Med Rev (2021). 2022. PMID: 37724326 Free PMC article. Review.
-
Associating Multimodal Neuroimaging Abnormalities With the Transcriptome and Neurotransmitter Signatures in Schizophrenia.Schizophr Bull. 2023 Nov 29;49(6):1554-1567. doi: 10.1093/schbul/sbad047. Schizophr Bull. 2023. PMID: 37607339
-
Stress, Environment and Early Psychosis.Curr Neuropharmacol. 2024;22(3):437-460. doi: 10.2174/1570159X21666230817153631. Curr Neuropharmacol. 2024. PMID: 37592817 Review.
-
The Immunoseasonal Theory of Psychiatric Disorders.J Clin Med. 2023 Jul 11;12(14):4615. doi: 10.3390/jcm12144615. J Clin Med. 2023. PMID: 37510730 Free PMC article.
References
-
- Weinberger DR, Lipska BK. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr Res. 1995;16:87–110 - PubMed
-
- Lewis DA, Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci. 2002;25:409–432 - PubMed
-
- Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry. 2005;10:434–449 - PubMed
-
- Murray RM, O’Callaghan E, Castle DJ, Lewis SW. A neurodevelopmental approach to the classification of schizophrenia. Schizophr Bull. 1992;18:319–332 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
